Please assess the completion status of the following clinical trial:

Trial Title: Treating Peritoneal Carcinomatosis With PIPAC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Histological or cytological verified malignancy.~* Clinical or radiological evidence of peritoneal carcinomatosis.~* No indication for standard chemotherapy.~* Performance status 0-2 and life expectancy of more than 3 months.~* Age \> 18 years.~* Written informed consent must be obtained according to the local Ethics Committee requirements.~Exclusion criteria~* Symptomatic small bowel obstruction (Total parenteral nutrition, nasogastric tube).~* Previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones.~* A history of allergic reaction to cisplatin or other platinum containing compounds or doxorubicin.~* Renal impairment, defined as GFR \< 50 ml/min, (Cockcroft-Gault Equation).~* Myocardial insufficiency, defined as NYHA class \> 2.~* Impaired liver function defined as bilirubin ≥ 1,5 x UNL (upper normal limit).~* Inadequate haematological function defined as ANC ≤ 1.5 x 109/l and platelets ≤ 100 x 109/l.~* Any other condition or therapy, which in the investigator's opinion may pose a risk to the patient or interfere with the study objectives.~* Previous intraabdominal chemotherapy or intraabdominal antibody therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PIPAC (Type: EXPERIMENTAL): PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides colorectal/appendiceal cancers in whom oxaliplatin (92mg/m2 in 150 ml dextrose) will be used.~The aerosolised chemotherapy will be nebulized at a flow of 0.5ml/min at a maximum pressure of 200 PSI during a standard laparoscopy with an intraabdominal pressure of 12mmHg. The CO2 will be evacuated 30 minutes after administration of chemotherapy and the patient is closed similar to a standard laparoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).